With the support of the Chinese Ministry of Science and Technology, and thanks to their 13-year painstaking efforts, researchers of Shanghai Institute of Materia Medica, part of the Chinese Academy of Sciences, have worked out a salvia polyphenol acetate injection. The finding has obtained patent grants issued by both Chinese and US patent authorities. On May 25, 2005, the Chinese State Food and Drug Administration issued a new drug certificate and associated approval for the commercial production of the drug.
Based on the in-depth study of the active components in Salvia miltiorrhiza Bunge, researchers made a fullest possible extraction of effective elements from the herbs. They produced salvia polyphenol acetate and associated injections, innovatively using modern herb extraction techniques and making the magnesium acetate a benchmark for quality control. Thanks to the advanced techniques used, researchers produced a salvia polyphenol acetate injection with a magnesium acetate content reaching as high as 80%, and an aggregate polyphenol acetate approaching 100%. Researchers secured a full range quality control on raw herbs, pharmaceutical ingredients, and drug preparation, using the fingerprint spectrum technique. Numerous clinical trials and studies have confirmed the fact that salvia polyphenol acetate and the injections using same elements are safe, efficient, and reliable in treating coronary and angina diseases. |
